Development of Selective Inhibitors for Aldehyde Dehydrogenases Based on Substituted Indole-2,3-diones by Kimble-Hill, Ann C. et al.
Development of Selective Inhibitors for Aldehyde Dehydrogenases
Based on Substituted Indole-2,3-diones
Ann C. Kimble-Hill,† Bibek Parajuli,† Che-Hong Chen,‡ Daria Mochly-Rosen,‡ and Thomas D. Hurley*,†
†Department of Biochemistry & Molecular Biology, Indiana University School of Medicine, MS4053, 635 Barnhill Drive, Indianapolis,
Indiana 46202, United States
‡Department of Chemical & Systems Biology, Stanford University School of Medicine, CCSR Room 3140, MC: 5174, 269 Campus
Drive, Stanford, California 94305, United States
*S Supporting Information
ABSTRACT: Aldehyde dehydrogenases (ALDH) participate in multiple
metabolic pathways and have been indicated to play a role in several
cancerous disease states. Our laboratory is interested in developing novel
and selective ALDH inhibitors. We looked to further work recently
published by developing a class of isoenzyme-selective inhibitors using
similar indole-2,3-diones that exhibit diﬀerential inhibition of ALDH1A1,
ALDH2, and ALDH3A1. Kinetic and X-ray crystallography data suggest
that these inhibitors are competitive against aldehyde binding, forming
direct interactions with active-site cysteine residues. The selectivity is
precise in that these compounds appear to interact directly with the
catalytic nucleophile, Cys243, in ALDH3A1 but not in ALDH2. In
ALDH2, the 3-keto group is surrounded by the adjacent Cys301/303.
Surprisingly, the orientation of the interaction changes depending on the
nature of the substitutions on the basic indole ring structure and correlates
well with the observed structure−activity relationships for each ALDH isoenzyme.
■ INTRODUCTION
Aldehyde dehydrogenases (ALDH) comprise a superfamily of
enzymes that catalyze the NAD(P)+-dependent oxidation of
aldehydes to their corresponding carboxylic acids.1 Enzymes in
this superfamily exhibit diversity in their speciﬁcity for
substrates. Detrimental changes in their contributions to
speciﬁc metabolic pathways lead to several disease states,
including Sjögren−Larsson syndrome, type II hyperprolinemia,
hyperammonemia, and alcohol ﬂushing disease as well as
cancer.2−6 Using known structural and catalytic attributes for
several of these family members has led to the discovery and
characterization of some selective chemical modulators for
ALDH27−9 and ALDH1/310,11 as well as broad-spectrum
modulators.12,13
Our prior work with a broad-spectrum inhibitor demon-
strated that the enzyme catalyzed production of a vinyl-ketone
intermediate that inhibited ALDH1A1, ALDH2, and
ALDH3A1 through the formation of a covalent adduct with
their catalytic cysteine residue.12 However, to achieve selective
inhibition of particular isoenzymes, molecules that do not rely
solely on common mechanistic features may be more desirable.
Therefore, this study looks to further that work by character-
izing a class of inhibitors that utilize a common mechanistic
feature but that can achieve selectivity through elaboration of
the common functional group, indole-2,3-dione. We report
here the kinetic and structural characterization of a diverse
group of substituted indole-2,3-diones, from which selective
inhibitors for ALDH1A1, ALDH2, and ALDH3A1 may be
derived.
■ RESULTS
Recently, we reported a class of compounds identiﬁed during a
high-throughput screen for modulators of ALDH2 that showed
nonselective covalent inhibition of ALDH isoenzymes.12 To
achieve a more selective inhibition of ALDH isoenzymes, we
reasoned that reliance on mechanistic features common to
ALDH family members was not desirable. Consequently, we re-
evaluated the original high-throughput screening results12,13 for
compounds that might demonstrate better isoenzyme selectiv-
ity. Re-examination of these screens led to the identiﬁcation of
four ALDH2 inhibitors with structural similarity to ﬁve
ALDH3A1 inhibitors, some of which showed excellent
selectivity toward ALDH3A1.13 To characterize this group of
compounds further, we obtained an additional 33 structurally
similar analogues from ChemDiv and ChemBridge and
evaluated their ability to inhibit ALDH1A1, ALDH2, and
ALDH3A1 using NAD(P)+-dependent aldehyde oxidation to
measure activity.
The compounds in this study are all derived from the indole-
2,3-dione parent compound, but three distinct structural
groupings can be created on the basis of the nature of the
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substitutions to the indole-2,3-dione ring system and their
ability to inhibit selected ALDH isoenzymes. Group 1 is
represented by substitutions that lack additional ring systems.
These were the least selective between ALDH isoenzymes and
exhibited low micromolar IC50 values for ALDH2 and middle-
to-high nanomolar IC50 values for ALDH1A1 and ALDH3A1
(Table 1).
Compounds in group 2 are characterized by the addition of a
benzyl moiety via an alkyl chain linker attached to the indole
ring nitrogen atom with and without halogen substitutions at
the 5-position of the indole ring. This group comprises the
most potent inhibitors of ALDH1A1 and ALDH2. However,
the nature of the substitutions can shift the potency 380-fold in
favor of ALDH1A1 or 40-fold in favor of ALDH2 (1-pentyl-2,3-
dihydro-1H-indole-2,3-dione (compound 3) vs 5-bromo-1-(2-
phenylethyl)-1H-indole-2,3-dione (compound 8), Table 1). In
general, longer alkyl-chain linkers favor ALDH1A1 and
ALDH3A1 inhibition. Halogens at the 5-position improve
potency toward ALDH2, but 5-bromo-substitutions on the
indole ring reduce the potency toward ALDH1A1. Substitution
of either a 5-chlorine or 5-bromine on the indole ring severely
reduces potency toward ALDH3A1 (1-(2-phenylethyl)-1H-
indole-2,3-dione (compound 6) vs 8, Table 1). The addition of
a double bond to the linker between the indole and benzyl rings
almost eliminates potency toward ALDH2 (1-(3-phenyl-2-
propen-1-yl)-1H-indole-2,3-dione (compound 10)), but in-
troduction of the 5-chloro group to the same molecule restores
potency (5-chloro-1-[(2E)-3-phenylprop-2-en-1-yl]-2,3-dihy-
dro-1H-indole-2,3-dione (compound 11)).
Group 3 compounds possess either a piperazine, morpholine,
or imidazolidine nonaromatic ring linked to the indole nitrogen
(Table 1). These compounds tend to be the most selective for
hALDH3A1 and show little if any inhibition of ALDH2. Only
the compound with a 5-bromo substitution on the indole ring
(1-{[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]methyl}-5-
bromo-1H-indole-2,3-dione (compound 21)) was a poor
inhibitor of hALDH3A1 (Table 1).
To understand the mechanism of inhibition for these
compounds better, compounds 1 and 3 were chosen as
representative compounds for substrate competition experi-
ments. These inhibitors exhibited noncompetitive mixed-type
inhibition with respect to varied coenzyme, and they exhibited
Table 1
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competitive inhibition with respect to varied aldehyde substrate
for all three ALDH isoenzymes (Tables 2 and 3).
Consistent with the kinetic data, the crystal structure of
ALDH2 with 3 and 1 bound shows that the compounds bound
within the aldehyde substrate binding site with the 3-keto group
sandwiched between the active-site cysteine residues 301 and
303 (Figures 1 and 2). The distance of interaction in these
models suggest that both cysteine residues are interacting
equivalently on either face of the carbonyl carbon but do not
appear to have formed formal adducts. There is no evidence of
any interaction with the side chain of Cys302. Interestingly, the
orientation of their indole-2,3-dione rings are ﬂipped such that
the opposing faces are interacting with Cys301 and Cys303 in
the 1 versus 3 structures. The 5-methyl substituent of 1 forms
hydrophobic interactions with the side chains of Trp177,
Leu173, and Met174, whereas the 7-bromo substituent is
oriented toward the solvent-exposed exit of the substrate-
binding site. In contrast, the 5-position of 3 is oriented toward
the solvent, and the 1-benzyl substituent is tucked tightly into
the substrate binding side adjacent to the side chain of Phe465,
which is displaced from the position found in all other ALDH2
crystal structures. There is an inverse correlation between
ordered positioning of the 1-N-benzyl group and that of
Phe465, suggesting that one or the other is mobile in this
complex. The close contacts between these aromatic rings is
likely responsible for the relatively high IC50 exhibited by
ALDH2 for 3. Despite the ﬂipped orientations of their common
ring system, the indole-2,3-diones of 1 and 3 maintain the same
aromatic π-stacking interactions with the side chains of Phe170
and Phe459.
In contrast, the crystal structure of ALDH3A1 in a complex
with 1-{[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-
methyl}-1H-indole-2,3-dione (compound 20) (Figure 3)
shows the 3-keto group of the indole-2,3-dione ring bound
within the substrate-binding site and forming an adduct with
the active-site nucleophile (Cys243 in ALDH3A1). The
distance between Cys243 and the carbonyl-carbon as well as
the out-of-plane displacement of the carbonyl oxygen is
consistent with the formation of an adduct between these
two reactive groups. That this covalent bond is reversible is
supported by the fact that addition of dithiothreitol to the
reaction solution after preincubation restores the enzymatic
activity. There is suﬃcient electron density to model the indole-
2,3-dione and the N-piperazine moiety, but insuﬃcient electron
density is present to model the terminal benzyl-dioxol moiety.
Computational placement of the benzyl-dioxol moiety onto the
crystallographically observed partial structure suggests that the
benzyl-dioxol lies at the interface between the exit of the
substrate-binding site and bulk solvent, where it can apparently
adopt multiple conformations.
■ DISCUSSION AND CONCLUSIONS
There are 19 members of the ALDH superfamily in the human
genome, with many of the family members participating in
deﬁned metabolic pathways, such as proline, valine, retinal,
folate, and GABA metabolism.1 In contrast, several members
have less well-deﬁned substrate preferences and constitute a
cellular defense system against endogenously and exogenously
generated aldehydes. In particular, ALDH1A1, ALDH2, and
ALDH3A1 demonstrate broad and overlapping substrate
speciﬁcities and are frequently expressed in the same tissues
or cell types.14 For instance, ALDH1A1 and ALDH3A1 have
both been shown to be biomarkers for cancer as well as cancer
stem cells.6,15 ALDH1A1 overexpression is indicative of high-
grade ductal carcinoma, multiple myeloma, and acute myeloid
leukemia.6,16−23 ALDH3A1 is generally found in stratiﬁed
Table 2. Kinetic Inhibition Data versus Varied Coenzyme
compound enzyme Ki (μM) α mode of inhibition
1 ALDH1 0.29 ± 0.05 1. 8 noncompetitive, mixed
ALDH2 2.2 ± 0.1 3.3
ALDH3 0.50 ± 0.2 1.1
3 ALDH2 34 ± 10 4.4 noncompetitive, mixed
ALDH3 4.0 ± 1 2.4
Table 3. Kinetic Inhibition Data versus Varied Aldehyde
compound enzyme Ki (μM) mode of inhibition
1 ALDH1 0.90 ± 0.1 competitive
ALDH2 1.0 ± 0.1
ALDH3 0.38 ± 0.05
3 ALDH2 15 ± 8 competitive
ALDH3 1.2 ± 0.1
Figure 1. Interactions of 1 with ALDH2. (A) Side view of the protein surface containing compound 1 (left) and (B) top view with the original
unbiased ﬁgure of merit, σA-weighted, 2Fo − Fc (blue; contoured at one standard deviation of the map) and Fo − Fc electron density map (green;
contoured at 2.5 standard deviations of the map) for 1 prior to its inclusion in the model superimposed on the ﬁnal reﬁned model.
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squamous epithelium,24−26 and both ALDH3A1 and
ALDH1A1 confer resistance to the cell-killing eﬀects of
cyclophosphamide.27,28 However, ALDH2 has primary con-
tributions to the elimination of acetaldehyde and to the
bioactivation of nitroglycerin.5,7,9,29−33 All three isoenzymes are
known to metabolize 4-hydroxynonenal.34,35 Thus, selective
inhibitors of these general aldehyde-oxidizing enzymes could
provide important research tools for the assessment of their
Figure 2. Interactions of 3 with ALDH2. (A) Side view of the protein surface containing compound 3 (left) and (B) top view with the original
unbiased ﬁgure of merit, σA-weighted, 2Fo − Fc (blue; contoured at one standard deviation of the map) and Fo − Fc electron density map (green;
contoured at 2.5 standard deviations of the map) for 3 prior to its inclusion in the model superimposed on the ﬁnal reﬁned model.
Figure 3. Interactions of 20 with ALDH3A1. (A) Side view of the protein surface containing the crystallgraphically observed portion of compound
20. (B) Top view with the original unbiased ﬁgure of merit, σA-weighted, 2Fo − Fc (blue; contoured at one standard deviation of the map) and Fo −
Fc electron density map (green; contoured at 2.5 standard deviations of the map) prior to its inclusion in the model superimposed on the ﬁnal
reﬁned model. There is insuﬃcient electron density to ﬁt and reﬁne properly the terminal benzyldioxol group in the structure. Consequently, we
have placed and reﬁned only that portion that can be accounted for by the available electron density.
Figure 4. Comparison of ALDiB interactions with active-site cysteines in ALDH2 and ALDH3A1. (A) Crystal structure of ALDH2 with 1 (gray) has
been overlaid with that of 3 (magenta) to show how the steric hindrance of the surrounding hydrophobic residues determines the mode of binding.
(B) Surface map of 3 (magenta) bound to ALDH2 (cyan) aligned to the crystallographically observed partial structure of 20 (orange) bound to
ALDH3A1 (yellow).
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individual contributions to their common substrates or cellular
functions. Toward this end, we have examined derivatives of
indole-2,3-diones for their ability to inhibit diﬀerentially these
three forms of ALDH.
Members of this class of compounds were identiﬁed in
separate inhibitory screens on ALDH2 and ALDH3A1,
although the diversity of the substitutions on the indole rings
of these initial hits suggested that selectivity could be achieved
through optimization of those substitutions. That this level of
selectivity could be achieved is further supported by the
diﬀerences in the chemical and surface topologies of their
respective substrate-binding sites. ALDH2 and ALDH3A1
share only ∼30% sequence identity, and despite sharing the
common catalytic residues they have distinct substrate-binding-
site characteristics (Figure 4). Similarly, ALDH2 and
ALDH1A1 share 68% sequence identity, and, although their
substrate-binding sites are both largely hydrophobic in nature,
the middle and exterior regions of the site in ALDH1A1 are
considerably wider because of smaller amino acid side chains at
positions 124 and 459.36,37 It is in this context that the
structure−activity relationships for these substituted indole-2,3-
diones should be interpreted.
The kinetic data is consistent with these inhibitors binding in
a manner that is competitive with respect to aldehyde binding.
Although the details of the interactions between the ALDiB
inhibitors and the enzymes diﬀer in the precise details, all
compounds occupy the substrate-binding site in a manner that
requires their displacement prior to productive binding of
substrate aldehydes. Their mixed-type noncompetitive inhib-
ition patterns with respect to varied coenzyme is consistent
with the largely ordered Bi−Bi mechanism followed by ALDH
family members that have been characterized in this
manner.38,39
The distinct diﬀerences in the nature of the interactions
between the indole-2,3-dione rings and ALDH3A1 and ALDH2
highlight the structural and functional diﬀerences of these
distantly related isoenzymes. Consistent with this level of
sequence identity, a structural alignment yields a rmsd of 2.1 Å
for 395 similarly positioned Cα atoms. The amino acids lining
their respective substrate-binding sites are both largely
hydrophobic, but the diﬀerences in their positioning and
identity create unique topographical features (Figures 3 and 4).
The manner in which 20 is bound within the ALDH3A1
substrate site also provides key information with respect to the
manner in which ALDH3A1 selectivity is achieved when
compared to the substrate-binding sites of ALDH1A1 and
ALDH2 (Figure 3). It is these structural and functional
diﬀerences that underlie the distinct way these substituted
indole-2,3-dione molecules bind to these ALDH active sites.
The 3-keto group in these inhibitory molecules is a well-known
electrophile, so it was not surprising that this group would seek
a reactive nucleophile within the ALDH active site. However, it
was surprising that only in ALDH3A1 did these compounds
form an adduct with the catalytic nucleophile, as the active site
of ALDH2 is generally thought to contain the stronger cysteine
nucleophile. ALDH2 generally exhibits low to submicromolar
Km values for aldehydes, whereas ALDH3A1 exhibits Km values
at least 2 orders of magnitude higher. Why then does 20 bind
to the catalytic nucleophile in ALDH3A1 but neither 1 nor 3
does so in ALDH2? An alignment of the respective active sites
demonstrates that in order for either 1 or 3 to bind to Cys302
the side chain of Trp177 has to move, but its position is
restricted by the side chains of Leu173, Met174, and Leu477
(Figure 4). This explains why the indole-2,3-dione ring cannot
bind productively to Cys302 in ALDH2 and why the SAR for
ALDH2 was so diﬃcult to understand before the structures of 1
and 3 were available.
The most diﬃcult features of the ALDH2 SAR to understand
were the favorability of larger halogens at the 5-position and
how the changes in inhibition strength varied as the alkyl linker
between the indole ring and a benzene substituent on the N1
position was lengthened. If the indole ring bound similarly to
that in ALDH3A1, then we would expect the SAR on halogens
at the 5-position to follow that of ALDH3A1; namely, that
larger halogens are detrimental to inhibitory potency (Table 1,
8 vs 5-chloro-1-(2-phenylethyl)-1H-indole-2,3-dione (com-
pound 7) vs 6, 20 vs 21). However, this is not the case for
ALDH2, as increasing the size of the halogen at the 5-position
either has little eﬀect (1-benzyl-5-bromo-1H-indole-2,3-dione
(compound 5), 1-benzyl-5-chloro-2,3-dihydro-1H-indole-2,3-
dione (compound 4), and 3, Table 1) or increases potency
(8 vs 7 vs 6, 10 vs 11, Table 1). In addition, lengthening the
alkyl linker to the benzene ring had no real impact on potency,
which is opposite that seen with aldehyde substrates where the
longer and more hydrophobic the alkyl chain, the better the
substrate. However, the presence of a double bond in this linker
virtually abolishes inhibitory potency (10 vs 1-(3-phenyl-
propyl)-1H-indole-2,3-dione (compound 9), Table 1), whereas
addition of a 5-chloro group to 10 (11) restores potency. This
data suggests that the binding modes for the halogen versus
non-halogen-substituted compounds diﬀer. We suggest that the
binding mode observed for 3 in ALDH2 is maintained for
group 2 compounds lacking halogens at the 5-position (Table
1), as the ability of the longer alkyl chains to adopt new
conformations necessary to exit the active site past the position
of Cys302 requires a ﬂexible linker. However, this binding
mode is inconsistent with the increased potency of halogen
substitution at the 5-position because the 5-position of 3 is
within van der Waals contact to Val120, Met124, and Phe296.
Consequently, the SAR would suggest that 5-halogen-
substituted group 2 compounds adopt the position observed
for 1, where the 5-methyl substituent will approximate the
position of the 5-chloro or 5-bromo substituents and the indole
nitrogen is now pointing toward the solvent-exposed exit of the
substrate-binding site.
In addition, the ALDH2 crystal structures presented here
show that Cys302 is pointing in the direction of the cofactor
pocket and away from the substrate pocket, which has been
referred to as the resting conformation.40 Lang et al. suggested
that this resting conformation contributes to Cys301/303
having the primary role in stimulation of the Cys302 thio-
carbonyl adduct formation, lowering the acidity of Cys302.30
Furthermore, comparison of ALDH2 with other enzyme family
members suggests that Cys303 interacts with substrates via
hydrogen bonding or by an ion−dipole interaction.14 The
crystal structures of 1 and 3 presented here suggest that
Cys301/303 may contribute to substrate binding through a
trapping mechanism and possibly by serving to dehydrate the
hydrated aldehydes that form in solution. Weiner and
colleagues proposed that elements of the enzyme’s proton-
relay system performed this function, but this proposal
preceded structure determination by 12 years.41,42 The
proton-relay system is identical in ALDH1A1 and ALDH3A1,
but the two residues immediately surrounding the catalytic
nucleophile in the active-site loop are not. In this regard,
ALDH1A1 has Ile at 301 and a single additional Cys residue at
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303, whereas ALDH3A1 lacks Cys residues at either equivalent
position (Thr and Val, respectively), which correlates with their
decreased catalytic eﬃciency for small aliphatic aldehydes with
the greatest level of hydration.43
In contrast to the complex SAR for ALDH2, selectivity for
ALDH3A1 is more simply achieved through the addition of a
nonaromatic ring system linked by a single carbon atom to the
indole nitrogen (Table 1). This addition to the indole ring
alone abrogates any potency toward ALDH2 and severely
diminishes potency toward ALDH1A1. Addition of hydro-
phobic substituents at the 4-position of the piperazine ring
further improves potency up to 4-fold (1-(4-morpholinylmeth-
yl)-1H-indole-2,3-dione (compound 12) versus 20) while still
maintaining a 40-fold selectivity over ALDH1A1. Although the
benzyl-dioxol substituent is disordered in our crystal structure,
presumably because of the multiple binding modes near the exit
of the substrate-binding site, these additional hydrophobic
substituents likely interact with the side chains of Trp233 and
Met237 (Figure 3). Substitution of the central nonaromatic
ring with an aromatic ring reduces potency by about 6-fold (3
versus 12). This is likely due to the generation of an
unfavorable steric contact between the aromatic ring and
Met237 (Figure 3). Addition of one or more additional linking
carbon atoms between the indole and aromatic rings improves
potency by more than 15-fold, presumably by bypassing the
restrictive space occupied by Met237 (3 vs 6 or 9, Table 1).
However, these changes come at the cost of selectivity for
ALDH3A1 as neither 6 nor 9 are selective inhibitors for
ALDH3A1. Another unique characteristic of ALDH3A1 is the
negative impact that substitution of large halogen atoms at the
5-position of the indole ring has on potency. This eﬀect can be
explained by the close proximity of the side chains of Phe401,
Tyr412, and His413 (Figure 3). Substitution of anything larger
than a hydrogen atom would crowd this location.
With the exception of the compounds in group 3, most
aliphatic or aromatic N-substituted indole-2,3-diones are potent
inhibitors of ALDH1A1 (Table 1). Only the substitution of a
nonaromatic ring linked to the indole nitrogen or the presence
of a 5-bromo group is detrimental to ALDH1A1 potency.
Consistent with its ability to oxidize retinaldehyde with high
eﬃciency, ALDH1A1 has the largest and most hydrophobic
substrate-binding site,36 and substituents on the indole nitrogen
that enhance hydrophobic interactions improve the potency of
these compounds toward this isoenzyme. The structure−
activity data for ALDH1A1 is consistent with a binding mode
for the substituted indole-2,3-diones that is similar to that for
20 in ALDH3A1. This data is supported by presence of Gly124
in ALDH1A1, rather than Met124 in ALDH2; this substitution
provides some additional room for a 5-chloro group but is still
insuﬃcient for a 5-bromo substitution, which would still clash
with Trp177. 3 is the most selective ALDH1A1 inhibitor
(Table 1).
The aim of this work was to develop further a new class of
small molecules that can be adapted to selectively inhibit
ALDH enzymes. As such, several compounds were identiﬁed
that show reasonable selectivity (>40-fold) toward ALDH1A1
(3), ALDH2 (8), or ALDH3A1 (20 or 1-{[4-(4-ﬂuorobenzyl)-
1-piperazinyl]methyl}-1H-indole-2,3-dione (compound 16))
based on the size and chemical characteristics of each
isoenzyme’s substrate-binding site. The competition assays
show that these inhibitors are noncompetitive with respect to
the coenzyme-binding site and are competitive toward the
substrate-binding site. X-ray crystallography data conﬁrms
inhibition occurs through direct interactions between the 3-
keto group of the indole ring and conserved cysteine residues
within the active site. Selective inhibition can be achieved
through substitutions at the C5 and N1 positions of the indole
ring system. These compounds may act as useful tools in
elucidating the contributions of individual ALDH isoenzymes
toward speciﬁc, as well as overlapping, metabolic pathways.
■ EXPERIMENTAL PROCEDURES
Materials. Compounds used for the inhibitor screen were found
using a 80% structure similarity search against 5-methyl-1H-indole-2,3-
dione using the PubChem project.44 The following compounds were
purchased from ChemBridge for further in vitro assay screening:
5301889, 1-benzyl-5-bromo-1H-indole-2,3-dione (5); 5192630, 1-(2-
phenylethyl)-1H-indole-2,3-dione (compound 6); 7196590, 5-chloro-
1-(2-phenylethyl)-1H-indole-2,3-dione (7); 6047303, 5-bromo-1-(2-
phenylethyl)-1H-indole-2,3-dione (8); 6378722, 7-bromo-5-methyl-
1H-indole-2,3-dione (1); 6433626, 1-(3-phenylpropyl)-1H-indole-2,3-
dione (9); 6997087, 1-(3-phenyl-2-propen-1-yl)-1H-indole-2,3-dione
(compound 10); 6505720, 1-{[4-(1,3-benzodioxol-5-ylmethyl)-1-
piperazinyl]methyl}-1H-indole-2,3-dione (20); 8918814, 1-{[4-(4-
ﬂuorobenzyl)-1-piperazinyl]methyl}-1H-indole-2,3-dione (16);
8918815, 1-{[4-(3-chlorobenzyl)-1-piperazinyl]methyl}-1H-indole-
2,3-dione (compound 18); 8918818, 1-{[4-(2-ﬂuorobenzyl)-1-
piperazinyl]methyl}-1H-indole-2,3-dione (compound 15); 8918819,
1-{[4-(3-ﬂuorobenzyl)-1-piperazinyl]methyl}-1H-indole-2,3-dione
(compound 17); 8919812, 1-{[4-(3-methoxybenzyl)-1-piperazinyl]-
methyl}-1H-indole-2,3-dione (compound 19); 6989645, 1-{[4-(1,3-
benzodioxol-5-ylmethyl)-1-piperazinyl]methyl}-5-bromo-1H-indole-
2,3-dione (21); 5250099, 1,1′-[1,3-imidazolidinediylbis(methylene)]-
bis(1H-indole-2,3-dione) (compound 22); 5115436, 1-(4-morpholi-
nylmethyl)-1H-indole-2,3-dione (12); 5260280, 1-[(4-methyl-1-
piperazinyl)methyl]-1H-indole-2,3-dione (compound 13); and
5115499, 1-[(4-benzyl-1-piperazinyl)methyl]-1H-indole-2,3-dione
(compound 14). The following compounds were purchased from
ChemDiv for further screening: 0764-0625, 1-pentyl-2,3-dihydro-1H-
indole-2,3-dione (compound 2); 0764-0628, 1-benzyl-2,3-dihydro-1H-
indole-2,3-dione (3); and 5353-0854, 1-benzyl-5-chloro-2,3-dihydro-
1H-indole-2,3-dione (4). On the basis of the SAR data collected,
compound BBV-138984, 5-chloro-1-[(2E)-3-phenylprop-2-en-1-yl]-
2,3-dihydro-1H-indole-2,3-dione (11), was purchased from MolPort
as proof of the selective-inhibition scheme. The NMR spectra
conﬁrming >95% compound purity provided by the vendors is
included in the Supporting Information. All other chemicals were
purchased from Sigma-Aldrich unless otherwise stated.
Protein Puriﬁcation. Human ALDH1A1 (hALDH1A1), ALDH2
(hALDH2), and ALDH3A1 (hALDH3A1) were expressed and
puriﬁed as described elsewhere.13,33,45,46
Inhibitor Screens. The ALDH2 and ALDH3A1 screening assays
have been reported previously.13 ALDH1A1 was screened using the
same assay as that of ALDH2. Inhibitors that emerged from the
screens were purchased from ChemBridge or ChemDiv.
Crystallization of ALDH3A1 and ALDH2 Complexes with
Inhibitors. Crystals of ALDH3A1 at 3 mg/mL in 10 mM HEPES, pH
7.5, were grown from solutions containing 0.2 M potassium acetate
and 18% PEG3350 at 25 °C. Enzyme complexes with inhibitors were
generated through direct-soaking experiments by ﬁrst equilibrating the
crystals overnight in a solution containing 2% DMSO, which was then
supplemented with 100 μM compound 20. The crystals were directly
frozen without any further addition of cryoprotectant.
Crystals of ALDH2 were grown from protein solutions containing 8
mg/mL of ALDH2 in 100 mM ACES, pH 6.2−6.8, 100 mM
guanidine-HCl, 10 mM MgCl2, and 14−19% PEG 6000. The ALDH2
complexes with inhibitors were generated through direct-soaking
experiments by ﬁrst equilibrating the crystals overnight in solutions
containing 2% DMSO, which was then supplemented with 100 μM of
either compound 1 or 3.
All diﬀraction data were collected at a wavelength of 0.9869 Å and
at 100 K. All diﬀraction data were indexed, integrated, and scaled using
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the HKL3000 program suite.47 Reﬁnement was performed using
Refmac5 within the CCP4 program suite.47,48 The structure of the
ALDH3A1 complex with 20 was solved by molecular replacement
using the ALDH3A1 apo structure (PDB code 3SZA). The presence
of inhibitor was determined after inspection of the initial σ-A weighted
Fo − Fc electron density maps. The structures of ALDH2 complexed
with 1 and 3 were solved using the coordinates of the reﬁned ALDH2
in the P21 space group after removal of solvent and ligands (1CW3).
Data collection and reﬁnement statistics are given in Table 4. The
ALDH2 complex with 1 demonstrates high-occupancy binding in
subunits A and H and insuﬃcient electron density for unequivocal
assignment in the remaining subunits. The ALDH2 complex with 3
shows high-occupancy binding in subunits A, B, E, and H and
insuﬃcient electron density for unequivocal assignment in the
remaining subunits.
IC50 Determination. IC50 inhibition curves for the inhibitors were
measured using the activity of hALDH2, hALDH1A1, and
hALDH3A1 as described elsewhere.13 In short, the enzyme was
incubated with the inhibitor and coenzyme for 2 min prior to initiation
of the reaction with aldehyde substrate. The inhibition curves were ﬁt
to the four-parameter EC50 equation using SigmaPlot (version 11,
StatSys). All data represent the average of three independent
experiments.
Determination of Mode of Inhibition. Inhibition of ALDH
activity was measured using the activity of hALDH2, hALDH1A1, and
hALDH3A1 to determine the kinetic mode of inhibition versus varied
coenzyme or aldehyde substrate. Coenzyme competition was
determined by measuring ALDH activity for various concentrations
of compound while varying the concentration of NAD+ for hALDH2
and hALDH1A1 and NADP+ for hALDH3A1. Likewise, substrate
competition was determined for diﬀerent concentrations of each
compound while varying propionaldehyde concentration for hALDH2
and hALDH1A1 and benzaldehyde concentration for hALDH3A1. In
each experiment, the concentration of the nonvaried substrate was set
to saturating levels, and the varied substrate concentration ranged at
least 10-fold spanning the calculated Km value. Similarly, the
concentration range for the inhibitors was varied a minimum of 5-
fold, exclusive of the control (no inhibitor) reactions, which spanned
the calculated Ki values. The kinetic mode of inhibition was
determined by ﬁtting data to the competitive, noncompetitive, and
uncompetitive inhibition equations and evaluating the goodness of ﬁt
to each equation.49 Data ﬁtting and analysis was performed using
SigmaPlot (version 11.0) with the enzyme kinetics module (version
1.3).
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Table 4. Data Collection and Reﬁnement Statistics
crystal ALDH2 + 1 ALDH2 + 3 ALDH3 + 20
PDB code 4KWG 4KWF 4L1O
Data Collection
beamline APS, GM/CA-CAT APS, GM/CA-CAT RAXIS IV+2
wavelength (Å) 0.98 0.98 1.54
space group P21 P21 P212121
cell dimensions (Å) a = 101.5 a = 102.3 a = 61.3
b = 176.2 b = 177.1 b = 86.4
c = 101.5 c = 102.6 c = 170.2
cell dimensions (deg) α = 90.00 α = 90.00 α = 90.0
β = 94.92 β = 94.39 β = 90.0
γ = 90.00 γ = 90.00 γ = 90.0
no. of reﬂections 193 565 150 293 39 454
resolution limit (Å) 2.00 (2.03 − 2.00) 2.3 (2.34−2.30) 2.3 (2.34−2.30)
completeness (%) 94.5 (85.9) 98.9 (97.0) 96.0 (88.0)
redundancy 3.5 (3.3) 3.1 (2.9) 3.4 (2.7)
mean I/σI 7.66 (19.3) 2.40 (12.88) 16.3 (6.7)
Rmerge (%) 5.8 (15.8) 7.2 (44.5) 6.0 (14.6)
Reﬁnement
resolution range (Å) 40.5−2.19 49.12−2.31 48 − 2.30
Rwork/Rfree (%) 19.3/22.9 23.9/29.6 17.5/22.2
no. of atoms
total 31 640 30 636 7610
protein 30 384 30 384 6913
ligand/ion 68 68 12
water 1162 188 649
inhibitor 26 72 36
average B-factors (Å2)
total 21.78 53.12 18.47
protein 21.37 53.10 18.4
ligand/ion 39.62 75.74 27.40/36.93
water 30.74 50.23 21.03
inhibitor 53.71 51.46 32.19
root-mean-square deviations
bond lengths (Å) 0.005 0.007 0.006
bond angles (deg) 0.969 1.188 1.143
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Accession Codes
The atomic coordinates and structure factors have been
deposited in the Protein Data Bank, Research Collaboratory
for Structural Bioinformatics, Rutgers University, New
Brunswick, New Jersey, with entry codes 4KWG, 4KWF, and
4L1O.
■ AUTHOR INFORMATION
Corresponding Author
*Tel: (317) 278-2008. E-mail: thurley@iu.edu.
Author Contributions
A.K.-H. performed experiments, data analysis, and manuscript
preparation; B.P. performed experiments and data analysis; C.-
H.C. performed experiments; D.M.-R. initiated the study and
manuscript preparation; and T.D.H. designed the study, data
analysis, and manuscript preparation.
Notes
The authors declare the following competing ﬁnancial
interest(s): Daria Mochly-Rosen and Che-Hong Chen are the
founders and shareholders of ALDEA Pharmaceuticals.
However, none of the work described in this study is based
on or supported by the company. Che-Hong Chen and Daria
Mochly-Rosen are listed as inventors in pending patents ﬁled
by Stanford University that are related to this work. Thomas D.
Hurley holds signiﬁcant ﬁnancial equity in SAJE Pharma, LLC.
However, none of the work described in this study is related to,
based on, or supported by the company.
■ ACKNOWLEDGMENTS
This work was supported in whole or in part by National
Institutes of Health grants R01-AA018123 and R21-AA019746
to T.D.H. and R01-AA11147 to D.M.-R. A.K.-H was supported
by R01-AA018123-S1. We thank Lan Chen and the Chemical
Genomics facility for access to their instrumentation. Results
shown in this article are derived from work performed at
Argonne National Laboratory, Structural Biology Center at the
Advanced Photon Source. Argonne is operated by UChicago
Argonne, LLC, for the U.S. Department of Energy, Oﬃce of
Biological and Environmental Research under contract DE-
AC02-06CH11357. We thank Stephan Ginell and Marianne
Cuﬀ for their assistance at SBC-CAT 19ID.
■ ABBREVIATIONS USED
ALDH, aldehyde dehydrogenase; DMSO, dimethyl sulfoxide;
EC50, half maximal eﬀective concentration; NAD, Nicotinamide
adenine dinucleotide; PEG, poly(ethylene glycol); SAR,
structure−activity relationship
■ REFERENCES
(1) Black, W.; Vasiliou, V. The aldehyde dehydrogenase gene
superfamily resource center. Hum. Genomics 2009, 4, 136−142.
(2) Vasiliou, V.; Pappa, A.; Petersen, D. R. Role of aldehyde
dehydrogenases in endogenous and xenobiotic metabolism. Chem.-
Biol. Interact. 2000, 129, 1−19.
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